(PSNL) – Business Wire
-
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
-
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
-
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
-
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
-
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
-
Personalis Reports Third Quarter 2023 Financial Results
-
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
-
Personalis to Announce Third Quarter 2023 Financial Results
-
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
-
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
-
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
-
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Reports Second Quarter 2023 Financial Results
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis to Announce Second Quarter 2023 Financial Results
-
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
-
Dr. Kenneth J. Widder Joins Personalis Board of Directors
-
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
-
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
-
Personalis Reports First Quarter 2023 Financial Results
-
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
-
Personalis to Announce First Quarter 2023 Financial Results
-
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
-
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
-
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
-
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
-
Personalis Appoints Christopher Hall as Chief Executive Officer
-
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
-
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
-
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Announces CEO Retirement and Transition
-
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
-
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
-
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
-
Personalis Reports Third Quarter 2022 Financial Results
-
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
-
Personalis to Announce Third Quarter 2022 Financial Results
-
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
Back to PSNL Stock Lookup
